Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Regulatory
Approvals worldwideDrug spendingDrug targets
Regulatory · NICE technology appraisal guidance · England

NICE technology appraisals

Every medicine and treatment NICE has appraised for the NHS in England since 2000: NICE's recommendation, when it was published, whether it still stands, and a link to the guidance and to the medicine's trials on this site.

Source: NICE technology appraisal guidance and NICE's appraisal recommendations data, shown with NICE's permission. Checked 3 Oct 2026
1,189Technology appraisals published
90%Of 897 current decided appraisals recommend for at least some patients
72Published in 2026 so far
976Linked to a medicine page here
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from NICE technology appraisal guidance · Last verified · Editorial standards

NICE has published 1,189 technology appraisals since 2000, and 1,062 of them are still current. Of the current appraisals where NICE reached a decision, 90% recommend the medicine or treatment for at least some patients, including through the Cancer Drugs Fund. The most recent is TA1189, published 26 Aug 2026. NICE's decisions apply to the NHS in England; in Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics.

01

What NICE decided

Appraisals by recommendation type
Recommended or optimised
836
Cancer Drugs Fund or Innovative Medicines Fund
64
Only in research
23
Not recommended
145
Terminated (no company submission)
177

An appraisal can contain several recommendations, for different groups of patients, so it can appear under more than one type. These explanations are ours; NICE's own definitions are on nice.org.uk.

02

All appraisals

1,189 appraisals, newest first, page 8 of 12
AppraisalMedicine pageNICE recommendationPublishedStatus
Vismodegib for treating basal cell carcinoma
NICE TA489
VismodegibNot recommended22 Nov 2017Current
Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
NICE TA488
RegorafenibOptimised15 Nov 2017Current
Venetoclax for treating chronic lymphocytic leukaemia
NICE TA487
VenetoclaxRecommended (Cancer Drugs Fund)8 Nov 2017Replaced by TA796
Aflibercept for treating choroidal neovascularisation
NICE TA486
AfliberceptRecommended1 Nov 2017Current
Sarilumab for moderate to severe rheumatoid arthritis
NICE TA485
SarilumabOptimised1 Nov 2017Current
Nivolumab for previously treated non-squamous non-small-cell lung cancer
NICE TA484
NivolumabRecommended (Cancer Drugs Fund)1 Nov 2017Current
Nivolumab for previously treated squamous non-small-cell lung cancer
NICE TA483
NivolumabRecommended (Cancer Drugs Fund)1 Nov 2017Current
Immunosuppressive therapy for kidney transplant in children and young people
NICE TA482
Basiliximab, Mycophenolate Mofetil, Tacrolimus, Sirolimus, Everolimus, BelataceptRecommended Not recommended11 Oct 2017Current
Immunosuppressive therapy for kidney transplant in adults
NICE TA481
Basiliximab, Mycophenolate Mofetil, Tacrolimus, Sirolimus, Everolimus, BelataceptRecommended Not recommended11 Oct 2017Current
Tofacitinib for moderate to severe rheumatoid arthritis
NICE TA480
TofacitinibOptimised11 Oct 2017Current
Reslizumab for treating severe eosinophilic asthma
NICE TA479
—Optimised4 Oct 2017Current
Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma
NICE TA478
Brentuximab VedotinOptimised4 Oct 2017Current
Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee
NICE TA477
—Optimised4 Oct 2017Current
Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer
NICE TA476
—Optimised6 Sep 2017Current
Dimethyl fumarate for treating moderate to severe plaque psoriasis
NICE TA475
—Optimised6 Sep 2017Current
Sorafenib for treating advanced hepatocellular carcinoma
NICE TA474
SorafenibOptimised6 Sep 2017Current
Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck
NICE TA473
CetuximabOptimised31 Aug 2017Current
Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab
NICE TA472
ObinutuzumabRecommended (Cancer Drugs Fund)30 Aug 2017Replaced by TA629
Eluxadoline for treating irritable bowel syndrome with diarrhoea
NICE TA471
—Recommended30 Aug 2017Current
Ofatumumab with chemotherapy for treating chronic lymphocytic leukaemia (terminated appraisal)
NICE TA470
OfatumumabTerminated (no company submission)23 Aug 2017Current
Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia (terminated appraisal)
NICE TA469
IdelalisibTerminated (no company submission)23 Aug 2017Current
Methylnaltrexone bromide for treating opioid-induced constipation (terminated appraisal)
NICE TA468
—Terminated (no company submission)23 Aug 2017Current
Holoclar for treating limbal stem cell deficiency after eye burns
NICE TA467
—Optimised Only in research16 Aug 2017Current
Baricitinib for moderate to severe rheumatoid arthritis
NICE TA466
BaricitinibOptimised9 Aug 2017Current
Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma
NICE TA465
—Recommended (Cancer Drugs Fund)9 Aug 2017Withdrawn
Bisphosphonates for treating osteoporosis
NICE TA464
BisphosphonatesOptimised9 Aug 2017
Updated 8 Jul 2019
Current
Cabozantinib for previously treated advanced renal cell carcinoma
NICE TA463
CabozantinibRecommended9 Aug 2017Current
Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma
NICE TA462
NivolumabRecommended26 Jul 2017Current
Roflumilast for treating chronic obstructive pulmonary disease
NICE TA461
—Optimised26 Jul 2017Current
Adalimumab and dexamethasone for treating non-infectious uveitis
NICE TA460
Adalimumab, DexamethasoneOptimised26 Jul 2017Current
Collagenase clostridium histolyticum for treating Dupuytren's contracture
NICE TA459
—Optimised26 Jul 2017Current
Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane
NICE TA458
Trastuzumab emtansineRecommended19 Jul 2017
Updated 20 Nov 2017
Current
Carfilzomib for previously treated multiple myeloma
NICE TA457
CarfilzomibOptimised19 Jul 2017Current
Ustekinumab for moderately to severely active Crohn’s disease after previous treatment
NICE TA456
UstekinumabRecommended12 Jul 2017Current
Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
NICE TA455
Adalimumab, Etanercept, UstekinumabOptimised12 Jul 2017Current
Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)
NICE TA454
DaratumumabTerminated (no company submission)5 Jul 2017Current
Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal)
NICE TA453
BortezomibTerminated (no company submission)5 Jul 2017Current
Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal)
NICE TA452
IbrutinibTerminated (no company submission)5 Jul 2017Current
Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia
NICE TA451
PonatinibRecommended28 Jun 2017Current
Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia
NICE TA450
BlinatumomabRecommended28 Jun 2017Current
Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
NICE TA449
Everolimus, SunitinibRecommended28 Jun 2017Current
Etelcalcetide for treating secondary hyperparathyroidism
NICE TA448
EtelcalcetideOptimised28 Jun 2017Current
Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
NICE TA447
PembrolizumabOptimised (Cancer Drugs Fund)28 Jun 2017Current
Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
NICE TA446
Brentuximab VedotinOptimised Optimised (Cancer Drugs Fund)28 Jun 2017Current
Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
NICE TA445
—Optimised24 May 2017Current
Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)
NICE TA444
AfatinibTerminated (no company submission)24 May 2017Current
Obeticholic acid for treating primary biliary cholangitis
NICE TA443
—Recommended26 Apr 2017Current
Ixekizumab for treating moderate to severe plaque psoriasis
NICE TA442
IxekizumabOptimised26 Apr 2017Current
Daclizumab for treating relapsing–remitting multiple sclerosis
NICE TA441
—Optimised26 Apr 2017Withdrawn
Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine
NICE TA440
—Not recommended26 Apr 2017Current
Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
NICE TA439
Cetuximab, PanitumumabRecommended29 Mar 2017
Updated 25 Sep 2017
Current
Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal)
NICE TA438
AlectinibTerminated (no company submission)29 Mar 2017Current
Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy (terminated appraisal)
NICE TA437
IbrutinibTerminated (no company submission)22 Mar 2017Current
Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal)
NICE TA436
BevacizumabTerminated (no company submission)22 Mar 2017Current
Tenofovir alafenamide for treating chronic hepatitis B (terminated appraisal)
NICE TA435
Tenofovir AlafenamideTerminated (no company submission)22 Mar 2017Current
Elotuzumab for previously treated multiple myeloma (terminated appraisal)
NICE TA434
ElotuzumabTerminated (no company submission)22 Mar 2017Current
Apremilast for treating active psoriatic arthritis
NICE TA433
ApremilastOptimised22 Feb 2017Current
Everolimus for advanced renal cell carcinoma after previous treatment
NICE TA432
EverolimusRecommended22 Feb 2017Current
Mepolizumab for treating severe refractory eosinophilic asthma
NICE TA431
—Optimised25 Jan 2017Current
Sofosbuvir–velpatasvir for treating chronic hepatitis C
NICE TA430
—Optimised25 Jan 2017Current
Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
NICE TA429
—Recommended25 Jan 2017Current
Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
NICE TA428
PembrolizumabOptimised11 Jan 2017
Updated 12 Sep 2017
Current
Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib
NICE TA427
PomalidomideRecommended11 Jan 2017Current
Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
NICE TA426
Dasatinib, Nilotinib, ImatinibRecommended21 Dec 2016Current
Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
NICE TA425
Dasatinib, Nilotinib, ImatinibOptimised Recommended Not recommended21 Dec 2016Current
Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
NICE TA424
PertuzumabRecommended21 Dec 2016Current
Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens
NICE TA423
EribulinOptimised21 Dec 2016Current
Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
NICE TA422
CrizotinibRecommended21 Dec 2016Current
Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
NICE TA421
EverolimusRecommended21 Dec 2016Current
Ticagrelor for preventing atherothrombotic events after myocardial infarction
NICE TA420
TicagrelorRecommended14 Dec 2016Current
Apremilast for treating moderate to severe plaque psoriasis
NICE TA419
ApremilastRecommended23 Nov 2016Current
Dapagliflozin in triple therapy for treating type 2 diabetes
NICE TA418
—Recommended23 Nov 2016Current
Nivolumab for previously treated advanced renal cell carcinoma
NICE TA417
NivolumabRecommended23 Nov 2016Current
Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer
NICE TA416
OsimertinibRecommended (Cancer Drugs Fund)26 Oct 2016Current
Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor
NICE TA415
Certolizumab PegolOptimised26 Oct 2016Current
Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma
NICE TA414
CobimetinibNot recommended26 Oct 2016Current
Elbasvir–grazoprevir for treating chronic hepatitis C
NICE TA413
—Recommended26 Oct 2016Current
Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases
NICE TA412
—Optimised28 Sep 2016Current
Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer
NICE TA411
NecitumumabNot recommended28 Sep 2016Current
Talimogene laherparepvec for treating unresectable metastatic melanoma
NICE TA410
Talimogene LaherparepvecOptimised28 Sep 2016Current
Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion
NICE TA409
AfliberceptRecommended28 Sep 2016Current
Pegaspargase for treating acute lymphoblastic leukaemia
NICE TA408
PegaspargaseOptimised28 Sep 2016Current
Secukinumab for treating active ankylosing spondylitis
NICE TA407
SecukinumabRecommended28 Sep 2016Current
Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
NICE TA406
CrizotinibRecommended28 Sep 2016Current
Trifluridine–tipiracil for previously treated metastatic colorectal cancer
NICE TA405
—Recommended24 Aug 2016Current
Degarelix for treating advanced hormone-dependent prostate cancer
NICE TA404
DegarelixOptimised24 Aug 2016Current
Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer
NICE TA403
RamucirumabNot recommended24 Aug 2016Current
Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin
NICE TA402
PemetrexedRecommended24 Aug 2016Current
Bosutinib for previously treated chronic myeloid leukaemia
NICE TA401
BosutinibRecommended24 Aug 2016Current
Nivolumab in combination with ipilimumab for treating advanced melanoma
NICE TA400
NivolumabRecommended27 Jul 2016Current
Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts
NICE TA399
AzacitidineNot recommended27 Jul 2016Current
Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation
NICE TA398
IvacaftorNot recommended27 Jul 2016Current
Belimumab for treating active autoantibody-positive systemic lupus erythematosus
NICE TA397
BelimumabOptimised22 Jun 2016Current
Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
NICE TA396
TrametinibRecommended22 Jun 2016Current
Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
NICE TA395
CeritinibRecommended22 Jun 2016Current
Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
NICE TA394
EvolocumabOptimised22 Jun 2016Current
Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
NICE TA393
AlirocumabOptimised22 Jun 2016Current
Adalimumab for treating moderate to severe hidradenitis suppurativa
NICE TA392
AdalimumabRecommended22 Jun 2016Current
Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
NICE TA391
CabazitaxelRecommended25 May 2016
Updated 24 Aug 2016
Current
Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
NICE TA390
Canagliflozin, DapagliflozinOptimised25 May 2016Current

Titles link to the guidance on nice.org.uk, where the full recommendations are. A medicine is linked to its page here only when the name NICE appraised is exactly the same molecule as ours; medicines given alongside it (“with chemotherapy”) are not counted as appraised. Appraisals of devices and procedures are listed but have no medicine page.

© NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

Medicines data, weekly

One email every Friday: new approvals, trials and shortages, with every figure linked to its source.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

NICE has allowed us to show the appraisal number, title, recommendation category and dates of each technology appraisal, with a link to the guidance. No guidance text is reproduced.

A nightly job reads NICE's recommendations data, reads each new appraisal page once and re-checks every page every 60 days for replaced or withdrawn guidance. It keeps the previous version if a refresh fails. No AI drafting. See our methodology. The NICE data on this page was last retrieved on 3 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.